Bristol Myers Squibb Company (BMY) vs Novartis AG (NVS)
Bristol Myers Squibb Company and Novartis AG are both Drug Manufacturers General companies. Novartis AG is the larger, with a market value of $264.3B against $125.9B — 2.1× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.8× against 21.8×. Bristol Myers Squibb Company grew revenue faster over the last twelve months: 3.11% against 2.73%. Novartis AG has the higher net margin (22.5% vs 18.9%) and the lower return on invested capital (13.1% vs 13.7%). Both pay a dividend; Bristol Myers Squibb Company yields more (5.04% vs 3.69%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 14 and Novartis AG on 9.
Valuation
Profitability
| Metric | BMY | NVS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 74.74% | 72.77% |
| Operating margin | 24.22% | 30.17% | 18.90% |
| Net margin | 18.87% | 22.50% | 8.27% |
| Free cash flow margin | 23.26% | 26.77% | 17.25% |
| Return on equity | 46.63% | 30.37% | 6.97% |
| Return on assets | 10.18% | 11.27% | 2.76% |
| Return on invested capital | 13.69% | 13.14% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack